{"id":"estrone","rwe":[{"pmid":"41905481","year":"2026","title":"Synthesis of 2-aryl/alkylaminomethyl 17-sulfamate/17-methyl estratrienes and their in vitro cytotoxicity in human cancer cell cultures.","finding":"","journal":"Steroids","studyType":"Clinical Study"},{"pmid":"41898861","year":"2026","title":"Transcriptional Activation of Estrogen Receptor-Alpha and Estrogen Receptor-Beta from Elephant Shark (Callorhynchus milii).","finding":"","journal":"Genes","studyType":"Clinical Study"},{"pmid":"41884656","year":"2025","title":"Review of the effect of atrazine on the HPG axes and steroidogenic pathways in males: relevance for testicular and prostate cancer.","finding":"","journal":"Frontiers in toxicology","studyType":"Clinical Study"},{"pmid":"41883375","year":"2026","title":"Per- and Polyfluoroalkyl Substance Exposure Associated with Later Puberty in Norwegian Girls: Data from the Bergen Growth Study 2.","finding":"","journal":"Environment & health (Washington, D.C.)","studyType":"Clinical Study"},{"pmid":"41876050","year":"2026","title":"Exploring the multiple photochemical behaviors of ionizable EDCs in aquatic environments: Kinetics, intermediates, and toxicity evolution.","finding":"","journal":"Environmental research","studyType":"Clinical Study"}],"_fda":{"id":"fcea41e7-b1a6-8718-e053-6294a90a117a","set_id":"09ff0633-2992-4aba-96ed-45a69f3ee589","openfda":{"unii":["2DI9HA706A","QDL83WN8C2","451W47IQ8X"],"route":["ORAL"],"spl_id":["fcea41e7-b1a6-8718-e053-6294a90a117a"],"brand_name":["Cyclease PMS"],"spl_set_id":["09ff0633-2992-4aba-96ed-45a69f3ee589"],"package_ndc":["0220-9081-04"],"product_ndc":["0220-9081"],"generic_name":["ESTRONE, SODIUM CHLORIDE, SEPIA OFFICINALIS JUICE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ESTRONE","SEPIA OFFICINALIS JUICE","SODIUM CHLORIDE"],"manufacturer_name":["Laboratoires Boiron"],"is_original_packager":[true]},"purpose":["Folliculinum 15C ...Relieves discomfort and aches associated with PMS Natrum muriaticum 12C ...Relieves water retention and irritability Sepia 12C...Relieves bloating and lower back pain."],"version":"6","stop_use":["Stop use and ask a doctor if symptoms persist for more than 7 days or worsen."],"warnings":["Enter section text here"],"questions":["Questions, Comments Boironusa.com info@boironusa.com 1-800-BOIRON-1 (1-800-264-7661) Distributed by Boiron, Inc. Newtown Square, PA 19073"],"ask_doctor":[""],"do_not_use":["Do not use if glued carton end flaps are open or if the blister seal is broken"],"when_using":[""],"how_supplied":["60 meltaway tablets"],"effective_time":"20230530","active_ingredient":["Folliculinum 15C HPUS (0.8mg), Natrum muriaticum 12C HPUS (0.8mg), Sepia 12C HPUS (0.8mg)"],"drug_interactions":["Safe - no side effects - no drug interactions - works naturally with your body"],"inactive_ingredient":["Croscarmellose sodium, lactose, magnesium stearate"],"storage_and_handling":["Store at 68-77 o F (30 o C)"],"indications_and_usage":["Temporary relieves premenstrual symptoms such as: bloating, water retention, minor aches, lower back pain, discomfort, emotional changes, irritability"],"spl_unclassified_section":["The letters \"HPUS\" indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States. *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE NOT ACCEPTED MEDICAL EVIDENCE. NOT FDA EVALUATED. **C,K,CK, and X are homeopathic dilutions: see BoironUSA.com/info for details."],"dosage_and_administration":["Adults and children 12 years of age and older: Dissolve 2 tablets in the mouth morning and evening until symptoms are relieved. Children under 12 years of age: Not recommended"],"spl_product_data_elements":["Cyclease PMS ESTRONE, SODIUM CHLORIDE, SEPIA OFFICINALIS JUICE CROSCARMELLOSE SODIUM LACTOSE MAGNESIUM STEARATE ESTRONE ESTRONE SODIUM CHLORIDE SODIUM CATION SEPIA OFFICINALIS JUICE SEPIA OFFICINALIS JUICE BOIRON ;"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding, ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children In case of accidental overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["label box"]},"tags":[{"label":"estrone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor","category":"target"},{"label":"ESR1","category":"gene"},{"label":"ESR2","category":"gene"},{"label":"HSD17B1","category":"gene"},{"label":"G03CA07","category":"atc"},{"label":"Oral","category":"route"},{"label":"Liquid","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Acne vulgaris","category":"indication"},{"label":"Chemotherapy-induced nausea and vomiting","category":"indication"},{"label":"Contraception","category":"indication"},{"label":"Prevention of Post-Operative Nausea and Vomiting","category":"indication"},{"label":"Prevention of Radiation-Induced Nausea and Vomiting","category":"indication"},{"label":"Watson Labs","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Estrogens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":39.987,"date":"","count":11,"signal":"Menopausal symptoms","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=40)"},{"llr":38.319,"date":"","count":28,"signal":"Hot flush","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=38)"},{"llr":24.915,"date":"","count":5,"signal":"Ophthalmic vein thrombosis","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=25)"},{"llr":22.57,"date":"","count":35,"signal":"Feeling abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=23)"},{"llr":21.194,"date":"","count":4,"signal":"Thyrotoxic periodic paralysis","source":"DrugCentral FAERS","actionTaken":"Reported 4 times (LLR=21)"},{"llr":19.033,"date":"","count":16,"signal":"Breast cancer","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=19)"},{"llr":16.85,"date":"","count":5,"signal":"Skin fragility","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=17)"}],"drugInteractions":[{"url":"/drug/atazanavir","drug":"atazanavir","action":"Monitor closely","effect":"May interact with Atazanavir","source":"DrugCentral","drugSlug":"atazanavir"},{"url":"/drug/darunavir","drug":"darunavir","action":"Monitor closely","effect":"May interact with Darunavir","source":"DrugCentral","drugSlug":"darunavir"},{"url":"/drug/fosamprenavir","drug":"fosamprenavir","action":"Monitor closely","effect":"May interact with Fosamprenavir","source":"DrugCentral","drugSlug":"fosamprenavir"},{"url":"/drug/fosphenytoin","drug":"fosphenytoin","action":"Monitor closely","effect":"May interact with Fosphenytoin Sodium","source":"DrugCentral","drugSlug":"fosphenytoin"},{"url":"/drug/letrozole","drug":"letrozole","action":"Avoid combination","effect":"May interact with Letrozole","source":"DrugCentral","drugSlug":"letrozole"},{"url":"/drug/nelfinavir","drug":"nelfinavir","action":"Monitor closely","effect":"May interact with Nelfinavir Mesylate","source":"DrugCentral","drugSlug":"nelfinavir"},{"url":"/drug/phenobarbital","drug":"phenobarbital","action":"Avoid combination","effect":"May interact with Phenobarbital","source":"DrugCentral","drugSlug":"phenobarbital"},{"url":"/drug/phenytoin","drug":"phenytoin","action":"Monitor closely","effect":"May interact with Phenytoin","source":"DrugCentral","drugSlug":"phenytoin"},{"url":"/drug/saquinavir","drug":"saquinavir","action":"Monitor closely","effect":"May interact with Saquinavir","source":"DrugCentral","drugSlug":"saquinavir"},{"url":"/drug/tipranavir","drug":"tipranavir","action":"Monitor closely","effect":"May interact with Tipranavir","source":"DrugCentral","drugSlug":"tipranavir"}],"commonSideEffects":[],"contraindications":["Angina pectoris","Asthma","Benign mammary dysplasia","Body fluid retention","Breast lump","Carcinoma of female breast","Cardiovascular event risk","Cerebrovascular accident","Chloasma","Cholestasis of pregnancy","Chorea","Deep venous thrombosis","Dementia","Depressive disorder","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Disorder of gallbladder","Endometrial carcinoma","Endometriosis","Epilepsy","Estrogen receptor positive tumor","Extrapyramidal disease","Family history of malignant neoplasm of breast","Functional visual loss"]},"trials":[],"aliases":[],"company":"Watson Labs","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ESTRONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:55:15.922543+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Estrone","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:55:22.555957+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:55:21.129505+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ESTRONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:55:21.495079+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:55:14.791386+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:55:14.791407+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL494753/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:55:22.206868+00:00"}},"allNames":"estron","offLabel":[],"synonyms":["estrone","estron","estrugenone","oestrin","oestrone"],"timeline":[{"date":"1979-02-21","type":"positive","source":"DrugCentral","milestone":"FDA approval (Watson Labs)"}],"approvals":[{"date":"1979-02-21","orphan":false,"company":"WATSON LABS","regulator":"FDA"}],"brandName":"Estron","ecosystem":[{"indication":"Acne vulgaris","otherDrugs":[{"name":"adapalene","slug":"adapalene","company":"Galderma Labs Lp"},{"name":"ammonia","slug":"ammonia","company":""},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"azelaic acid","slug":"azelaic-acid","company":"Allergan"}],"globalPrevalence":null},{"indication":"Chemotherapy-induced nausea and vomiting","otherDrugs":[{"name":"aprepitant","slug":"aprepitant","company":"Merck"},{"name":"dronabinol","slug":"dronabinol","company":"Abbvie"},{"name":"fosaprepitant","slug":"fosaprepitant","company":""},{"name":"fosnetupitant","slug":"fosnetupitant","company":"Helsinn Hlthcare"}],"globalPrevalence":null},{"indication":"Contraception","otherDrugs":[{"name":"desogestrel","slug":"desogestrel","company":"Organon Usa Inc"},{"name":"dienogest","slug":"dienogest","company":""},{"name":"drospirenone","slug":"drospirenone","company":"Exeltis Usa Inc"},{"name":"estradiol","slug":"estradiol","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Prevention of Post-Operative Nausea and Vomiting","otherDrugs":[{"name":"aprepitant","slug":"aprepitant","company":"Merck"},{"name":"dolasetron","slug":"dolasetron","company":"Sanofi Aventis Us"},{"name":"granisetron","slug":"granisetron","company":"Roche"},{"name":"metoclopramide","slug":"metoclopramide","company":"Baxter Hlthcare Corp"}],"globalPrevalence":null},{"indication":"Prevention of Radiation-Induced Nausea and Vomiting","otherDrugs":[{"name":"granisetron","slug":"granisetron","company":"Roche"},{"name":"ondansetron","slug":"ondansetron","company":"Novartis Pharms Corp"}],"globalPrevalence":null}],"mechanism":{"target":"Estrogen receptor","novelty":"Follow-on","targets":[{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"},{"gene":"ESR2","source":"DrugCentral","target":"Estrogen receptor beta","protein":"Estrogen receptor beta"},{"gene":"HSD17B1","source":"DrugCentral","target":"Estradiol 17-beta-dehydrogenase 1","protein":"Estradiol 17-beta-dehydrogenase 1"},{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"},{"gene":"CYP19A1","source":"DrugCentral","target":"Aromatase","protein":"Aromatase"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"SERPINA6","source":"DrugCentral","target":"Corticosteroid-binding globulin","protein":"Corticosteroid-binding globulin"},{"gene":"STS","source":"DrugCentral","target":"Steryl-sulfatase","protein":"Steryl-sulfatase"},{"gene":"SNCA","source":"DrugCentral","target":"Alpha-synuclein","protein":"Alpha-synuclein"}],"modality":"Small Molecule","drugClass":"estrone","explanation":"","oneSentence":"","technicalDetail":"Estron exerts its effects by competitively binding to estrogen receptors, specifically ERα and ERβ, which are transcription factors that regulate gene expression in response to estrogen."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cellulose_acetate","title":"Cellulose acetate","extract":"In biochemistry, cellulose acetate refers to any acetate ester of cellulose, usually cellulose diacetate. It was first prepared in 1865. A bioplastic, cellulose acetate is used as a film base in photography, as a component in some coatings, and as a frame material for eyeglasses; it is also used as a synthetic fiber in the manufacture of cigarette filters and playing cards. In photographic film, cellulose acetate film replaced nitrate film in the 1950s, being far less flammable and cheaper to produce.","wiki_history":"==History==\nIn 1865, French chemist Paul Schützenberger discovered that cellulose reacts with acetic anhydride to form cellulose acetate. The German chemists Arthur Eichengrün and Theodore Becker invented the first soluble forms of cellulose acetate in 1903.\n\nIn 1904, Camille Dreyfus and his younger brother Henri performed chemical research and development on cellulose acetate in a shed in their father's garden in Basel, Switzerland, which was then a center of the dye industry. For five years, the Dreyfus brothers studied and experimented in a systematic manner in Switzerland and France. By 1910, they were producing film for the motion picture industry, and a small but constantly growing amount of acetate lacquer, called \"dope\", was sold to the expanding aircraft industry to coat the fabric covering wings and fuselage.\n\nIn 1913, after some twenty thousand separate experiments, they produced excellent laboratory samples of continuous filament yarn, something that had eluded the cellulose acetate industry to this time. Unfortunately, the outbreak of World War I postponed commercial development of this process.\n\nIn November 1914, the British Government invited Camille Dreyfus to come to England to manufacture acetate dope, and the \"British Cellulose and Chemical Manufacturing Co\" was set up. In 1917, after the United States had entered the war, the U.S. War Department invited Dreyfus to establish a similar factory in the U.S. Both operations were run successfully throughout the war.\n\nAfter the war, attention returned to the production of acetate fibers. The first yarn was of fair quality, but sales resistance was heavy, and silk associates worked zealously to discredit acetate and discourage its use. However, the thermoplastic nature of acetate made it an excellent fiber for moiré because the pattern was permanent and did not wash away. The same characteristic also made permanent pleating a commercial fact for the first time, and gave great style impetus to the wh"},"commercial":{"launchDate":"1979","_launchSource":"DrugCentral (FDA 1979-02-21, WATSON LABS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3188","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ESTRONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ESTRONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Cellulose_acetate","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:14:03.755899","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:55:24.876429+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ethinylestradiol","drugSlug":"ethinylestradiol","fdaApproval":"1943-06-25","relationship":"same-class"},{"drugName":"estradiol","drugSlug":"estradiol","fdaApproval":"1975-07-23","patentExpiry":"Nov 21, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"estriol","drugSlug":"estriol","fdaApproval":"","relationship":"same-class"},{"drugName":"chlorotrianisene","drugSlug":"chlorotrianisene","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"conjugated estrogens","drugSlug":"conjugated-estrogens","fdaApproval":"1942-05-08","relationship":"same-class"}],"genericName":"estrone","indications":{"approved":[{"name":"Acne vulgaris","source":"DrugCentral","snomedId":88616000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Chemotherapy-induced nausea and vomiting","source":"DrugCentral","snomedId":236084000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Contraception","source":"DrugCentral","snomedId":13197004,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Prevention of Post-Operative Nausea and Vomiting","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Prevention of Radiation-Induced Nausea and Vomiting","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[{"name":"Abnormal uterine bleeding unrelated to menstrual cycle","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Amenorrhea","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":189,"evidenceLevel":"strong"},{"name":"Dysmenorrhea","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":12,"evidenceLevel":"moderate"},{"name":"Excessive vomiting in pregnancy","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Female hypogonadism syndrome","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":16,"evidenceLevel":"moderate"},{"name":"Menopausal flushing","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":78,"evidenceLevel":"strong"},{"name":"Menorrhagia","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":7,"evidenceLevel":"emerging"},{"name":"Polycystic ovaries","source":"DrugCentral","drugName":"ESTRONE","evidenceCount":259,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ethinylestradiol","brandName":"ethinylestradiol","genericName":"ethinylestradiol","approvalYear":"1943","relationship":"same-class"},{"drugId":"estradiol","brandName":"estradiol","genericName":"estradiol","approvalYear":"1975","relationship":"same-class"},{"drugId":"estriol","brandName":"estriol","genericName":"estriol","approvalYear":"","relationship":"same-class"},{"drugId":"chlorotrianisene","brandName":"chlorotrianisene","genericName":"chlorotrianisene","approvalYear":"","relationship":"same-class"},{"drugId":"conjugated-estrogens","brandName":"conjugated estrogens","genericName":"conjugated estrogens","approvalYear":"1942","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":["Fertility"],"enrollment":24,"completionDate":"2026-03-09"},{"nctId":"NCT06513104","phase":"PHASE1","title":"A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-07-18","conditions":["Diabetes Mellitus, Type 2"],"enrollment":47,"completionDate":"2025-09-30"},{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":["Healthy Participants"],"enrollment":75,"completionDate":"2026-12-25"},{"nctId":"NCT07414784","phase":"PHASE1","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-02-11","conditions":["Healthy Volunteer"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT07388511","phase":"PHASE1","title":"A Study of Elenestinib in Healthy Adult Female Participants","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2026-02-03","conditions":["Healthy Participants"],"enrollment":20,"completionDate":"2026-04-01"},{"nctId":"NCT00455156","phase":"PHASE3","title":"Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring","status":"COMPLETED","sponsor":"Premier Research","startDate":"2006-12","conditions":["Contraception"],"enrollment":1200,"completionDate":"2011-09"},{"nctId":"NCT07340190","phase":"PHASE1","title":"A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":["Advanced Malignancies"],"enrollment":24,"completionDate":"2029-12-14"},{"nctId":"NCT03106454","phase":"PHASE3","title":"Ovulation Incidence in Oral Contraceptive Users","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2014-08","conditions":["Contraception","Ovulation"],"enrollment":58,"completionDate":"2024-01-01"},{"nctId":"NCT05877235","phase":"NA","title":"Serum Concentration of Endogenous Estrogens and Sirtuin-1 After Administration of Atorvastatin and Quercetin:","status":"COMPLETED","sponsor":"InCor Heart Institute","startDate":"2021-10-03","conditions":["Coronary Artery Disease","Menopause"],"enrollment":60,"completionDate":"2024-06-23"},{"nctId":"NCT07242131","phase":"NA","title":"Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS","status":"RECRUITING","sponsor":"Ege University","startDate":"2025-12-01","conditions":["Polycystic Ovary Syndrome (PCOS)"],"enrollment":150,"completionDate":"2026-06-01"},{"nctId":"NCT03043924","phase":"NA","title":"Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2017-09-26","conditions":["Polycystic Ovary Syndrome"],"enrollment":52,"completionDate":"2022-04-15"},{"nctId":"NCT07083635","phase":"PHASE2","title":"Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users","status":"RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-07-29","conditions":["Menstruation Disturbances","Metrorrhagia","Uterine Hemorrhage","Contraception Behavior"],"enrollment":40,"completionDate":"2026-12"},{"nctId":"NCT07190430","phase":"PHASE1","title":"A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":["Atopic Dermatitis"],"enrollment":16,"completionDate":"2025-12-15"},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":["HIV Infections"],"enrollment":1578,"completionDate":"2020-09-30"},{"nctId":"NCT02892942","phase":"PHASE4","title":"NATural Ovarian Stimulation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-13","conditions":["Infertility"],"enrollment":129,"completionDate":"2019-02-08"},{"nctId":"NCT07215806","phase":"PHASE1","title":"Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-08-24","conditions":["Healthy"],"enrollment":20,"completionDate":"2022-11-25"},{"nctId":"NCT05095597","phase":"PHASE2","title":"Umbilical Cord Plasma for Treating Endometrial Pathologies (Thin Endometrium / Asherman's Syndrome/ Endometria Atrophy)","status":"COMPLETED","sponsor":"Fundación IVI","startDate":"2022-04-22","conditions":["Asherman Syndrome","Endometrial Atrophy"],"enrollment":15,"completionDate":"2025-01-27"},{"nctId":"NCT04255277","phase":"PHASE1","title":"To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2020-01-31","conditions":["Healthy Subjects"],"enrollment":97,"completionDate":"2021-10-18"},{"nctId":"NCT07181343","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)","status":"COMPLETED","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-05-28","conditions":["Psoriasis (PsO)"],"enrollment":18,"completionDate":"2025-08-19"},{"nctId":"NCT06334315","phase":"PHASE4","title":"Oral Contraceptive Pill (OCP) Pharmacogenomics","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-10-29","conditions":["Contraception","Pharmacogenomic Drug Interaction"],"enrollment":700,"completionDate":"2028-05"},{"nctId":"NCT06071442","phase":"PHASE1","title":"Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-17","conditions":["Healthy Participants"],"enrollment":60,"completionDate":"2024-04-12"},{"nctId":"NCT07061093","phase":"","title":"Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observational Study","status":"RECRUITING","sponsor":"Ospedale Policlinico San Martino","startDate":"2023-10-10","conditions":["Cardiovascular System Diseases (&Amp; [Cardiac])"],"enrollment":96,"completionDate":"2026-01-31"},{"nctId":"NCT04972396","phase":"PHASE1","title":"Pemvidutide (ALT-801) DDI Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2021-09-15","conditions":["NASH - Nonalcoholic Steatohepatitis"],"enrollment":40,"completionDate":"2022-05-15"},{"nctId":"NCT01246791","phase":"PHASE3","title":"Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2010-11","conditions":["Healthy"],"enrollment":12,"completionDate":"2011-05"},{"nctId":"NCT05002738","phase":"PHASE4","title":"Desogestrel-containing COCP Pharmacokinetic Validation Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-09-10","conditions":["Contraception"],"enrollment":22,"completionDate":"2022-11-28"},{"nctId":"NCT06396221","phase":"NA","title":"\"Quick-starting\" of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-05-01","conditions":["Ultrasound Finding: Ovulation Inhibition, Ovarian Activities","Cervical Mucus","Serum Hormonal Profile"],"enrollment":36,"completionDate":"2024-09-30"},{"nctId":"NCT06396208","phase":"NA","title":"\"Quick-starting\" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-05-01","conditions":["Ultrasound Finding: Ovulation Inhibition, Ovarian Activities","Cervical Mucus","Serum Hormonal Profile"],"enrollment":40,"completionDate":"2024-10-31"},{"nctId":"NCT06461039","phase":"PHASE1","title":"A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-06-14","conditions":["Obesity"],"enrollment":43,"completionDate":"2025-04-04"},{"nctId":"NCT03249402","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2017-08-14","conditions":["Healthy"],"enrollment":24,"completionDate":"2017-11-24"},{"nctId":"NCT06671405","phase":"PHASE1","title":"An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-25","conditions":["Dyslipidaemia"],"enrollment":59,"completionDate":"2025-02-17"},{"nctId":"NCT03547024","phase":"PHASE1","title":"A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2018-06-08","conditions":["Healthy"],"enrollment":14,"completionDate":"2018-08-30"},{"nctId":"NCT05706753","phase":"PHASE1","title":"A Study of Milvexian in Healthy Adult Females","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2023-01-25","conditions":["Healthy Female"],"enrollment":20,"completionDate":"2023-07-20"},{"nctId":"NCT06799884","phase":"PHASE1","title":"A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2025-01-18","conditions":["Drug Drug Interaction"],"enrollment":19,"completionDate":"2025-02-21"},{"nctId":"NCT01253824","phase":"PHASE3","title":"Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2011-01","conditions":["Healthy"],"enrollment":14,"completionDate":"2011-07"},{"nctId":"NCT06188026","phase":"PHASE1","title":"A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-12-18","conditions":["Healthy Volunteers (Non-alcoholic Steatohepatitis)"],"enrollment":34,"completionDate":"2024-12-30"},{"nctId":"NCT06783192","phase":"PHASE1","title":"A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-14","conditions":["Human Immunodeficiency Virus (HIV)","HIV Pre-Exposure Prophylaxis"],"enrollment":14,"completionDate":"2023-10-11"},{"nctId":"NCT06145438","phase":"PHASE3","title":"Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery","status":"COMPLETED","sponsor":"Universitas Diponegoro","startDate":"2023-09-04","conditions":["Endometriosis Ovary"],"enrollment":80,"completionDate":"2024-11-19"},{"nctId":"NCT05058872","phase":"PHASE4","title":"Contraceptive Hormone and Reward Measurement (CHARM Study)","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-10-01","conditions":["Oral Hormonal Contraceptive Use","Neural Activity","Mood","Hedonic Function"],"enrollment":144,"completionDate":"2027-03-31"},{"nctId":"NCT05960370","phase":"","title":"Impact of Endometrial Compaction on Reproductive Outcomes After Cryotransfer of Euploid Embryos in a Natural Cycle","status":"RECRUITING","sponsor":"Instituto Bernabeu","startDate":"2022-06-15","conditions":["Infertility Due to Nonimplantation"],"enrollment":206,"completionDate":"2025-06-15"},{"nctId":"NCT05098574","phase":"PHASE2","title":"Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2023-02-03","conditions":["Premenstrual Dysphoric Disorder","Bipolar Disorder"],"enrollment":17,"completionDate":"2024-04-11"},{"nctId":"NCT06250205","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-02-05","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2024-04-26"},{"nctId":"NCT03557619","phase":"PHASE1","title":"A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2019-07-30","conditions":["Hematologic Malignancies"],"enrollment":12,"completionDate":"2026-03-21"},{"nctId":"NCT05093205","phase":"PHASE1","title":"STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-25","conditions":["Healthy Adults"],"enrollment":35,"completionDate":"2022-07-06"},{"nctId":"NCT06039826","phase":"PHASE1","title":"A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-09-12","conditions":["Overweight"],"enrollment":46,"completionDate":"2024-07-11"},{"nctId":"NCT02400801","phase":"NA","title":"Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-06","conditions":["Endometriosis","Infertility"],"enrollment":166,"completionDate":"2018-01-26"},{"nctId":"NCT06380205","phase":"PHASE1","title":"A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-05-07","conditions":["Healthy Participants"],"enrollment":24,"completionDate":"2024-06-07"},{"nctId":"NCT01656434","phase":"PHASE3","title":"Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2012-11-02","conditions":["Contraception"],"enrollment":3173,"completionDate":"2014-02-12"},{"nctId":"NCT05872425","phase":"NA","title":"Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS","status":"COMPLETED","sponsor":"Guangdong Women and Children Hospital","startDate":"2023-02-01","conditions":["PCOS"],"enrollment":120,"completionDate":"2024-04-01"},{"nctId":"NCT01709318","phase":"PHASE2","title":"A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-12","conditions":["Contraception"],"enrollment":666,"completionDate":"2013-10-22"},{"nctId":"NCT01490190","phase":"PHASE4","title":"Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-12-26","conditions":["Contraception"],"enrollment":252,"completionDate":"2012-12-05"},{"nctId":"NCT06316206","phase":"PHASE4","title":"The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":["Endometrial Polyp","Endometrial Diseases"],"enrollment":80,"completionDate":"2024-03-01"},{"nctId":"NCT06324851","phase":"PHASE4","title":"The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2023-01-01","conditions":["Endometrial Polyp","Endometrial Diseases"],"enrollment":150,"completionDate":"2024-03-01"},{"nctId":"NCT06346457","phase":"","title":"Breast Cancer & Antiestrogenic Therapy & Brain","status":"NOT_YET_RECRUITING","sponsor":"International Research Training Group 2804","startDate":"2024-04-01","conditions":["Breast Cancer Female","Healthy Female","Menopause","Anti-estrogenic Therapy"],"enrollment":180,"completionDate":"2026-04-01"},{"nctId":"NCT03684096","phase":"NA","title":"Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2018-10-15","conditions":["Breast Cancer","Hot Flashes","Postmenopausal Symptoms"],"enrollment":69,"completionDate":"2023-01-31"},{"nctId":"NCT04007874","phase":"PHASE3","title":"Oral Contraceptive Pill Compared With Vitamin E in Women With Migraine","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2019-09-10","conditions":["Migraine","Migraine;Menstrual"],"enrollment":360,"completionDate":"2024-12"},{"nctId":"NCT03945513","phase":"PHASE3","title":"A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles","status":"COMPLETED","sponsor":"Insud Pharma","startDate":"2019-12-03","conditions":["Contraception"],"enrollment":1034,"completionDate":"2023-09-08"},{"nctId":"NCT06067256","phase":"PHASE4","title":"A Multicentre, Prospective, Open-label, Non-comparative Study","status":"UNKNOWN","sponsor":"Italfarmaco","startDate":"2023-07-20","conditions":["Contraception"],"enrollment":228,"completionDate":"2024-06"},{"nctId":"NCT05064332","phase":"PHASE1","title":"A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-08","conditions":["Healthy"],"enrollment":10,"completionDate":"2021-12-16"},{"nctId":"NCT05891262","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-06","conditions":["Healthy Female Volunteers"],"enrollment":15,"completionDate":"2023-08-25"},{"nctId":"NCT02672826","phase":"NA","title":"Description of the Endothelial Phenotypes From the Subcutaneous Abdominal and Gluteo-femoral Adipose Tissues in Women","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-06-01","conditions":["Obesity"],"enrollment":50,"completionDate":"2016-12"},{"nctId":"NCT02352090","phase":"PHASE4","title":"Synthetic vs Natural Estrogen in Combined Oral Contraception","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2015-04-01","conditions":["Contraception"],"enrollment":59,"completionDate":"2018-12-30"},{"nctId":"NCT03074045","phase":"PHASE3","title":"LCS16 vs. COC User Satisfaction and Tolerability Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-03-13","conditions":["Contraception"],"enrollment":145,"completionDate":"2022-08-05"},{"nctId":"NCT04539626","phase":"NA","title":"Estrogen Therapy in Non-severe COVID-19 Patients","status":"UNKNOWN","sponsor":"CMN \"20 de Noviembre\"","startDate":"2020-10-01","conditions":["Covid-19"],"enrollment":44,"completionDate":"2023-12-31"},{"nctId":"NCT05788952","phase":"","title":"The Role of Intestinal and Vaginal Microbiota, Estrogenic Activity, Metabolic Profile & Nutritional Status in Endometriosis","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2023-06-01","conditions":["Endometriosis"],"enrollment":60,"completionDate":"2024-12-01"},{"nctId":"NCT05762042","phase":"NA","title":"Comparison of the Efficacy and Tolerability of Femal Versus Placebo","status":"COMPLETED","sponsor":"Azienda Ospedaliera Ordine Mauriziano di Torino","startDate":"2019-05-10","conditions":["Breast Cancer","Menopause"],"enrollment":34,"completionDate":"2022-04-01"},{"nctId":"NCT04984070","phase":"NA","title":"Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":["PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","Depression, Anxiety"],"enrollment":100,"completionDate":"2024-12-31"},{"nctId":"NCT05493202","phase":"","title":"Superovulation And Urinary Concentration of Estrone","status":"COMPLETED","sponsor":"Olive Fertility Centre","startDate":"2022-02-20","conditions":["in Vitro Fertilization","Hormone Testing"],"enrollment":30,"completionDate":"2022-07-30"},{"nctId":"NCT02460445","phase":"NA","title":"Phlebotomy and Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Manuel Luque Ramírez","startDate":"2015-01","conditions":["Hyperandrogenism","Metabolic Cardiovascular Syndrome"],"enrollment":37,"completionDate":"2020-06"},{"nctId":"NCT05282940","phase":"PHASE1","title":"Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2022-02-26","conditions":["Therapeutic Equivalency"],"enrollment":36,"completionDate":"2022-04-08"},{"nctId":"NCT02705963","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-10-20","conditions":["Solid Tumors"],"enrollment":19,"completionDate":"2019-08-29"},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":["Contraception"],"enrollment":24,"completionDate":"2004-06"},{"nctId":"NCT01005056","phase":"","title":"Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":["Contraception"],"enrollment":3838,"completionDate":"2009-03"},{"nctId":"NCT00711607","phase":"PHASE1","title":"A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":["Healthy"],"enrollment":25,"completionDate":"2007-09-01"},{"nctId":"NCT00647933","phase":"PHASE1","title":"An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-06","conditions":["Infertility"],"enrollment":24,"completionDate":"2000-12"},{"nctId":"NCT04964193","phase":"NA","title":"Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers","status":"COMPLETED","sponsor":"PT Sydna Farma","startDate":"2019-03-12","conditions":["Drug Use"],"enrollment":24,"completionDate":"2019-09-26"},{"nctId":"NCT01873170","phase":"","title":"Quantification of Immune Cells in Women Using Contraception (CHIC II)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-08","conditions":["HIV","Immune Cells (Mucosal and Systemic)","Contraception"],"enrollment":326,"completionDate":"2020-10"},{"nctId":"NCT01291004","phase":"PHASE1","title":"A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-01-31","conditions":["Follicle Development","Ovarian Follicle","Follicle Count","Follicle Size","Oral Contraceptive"],"enrollment":206,"completionDate":"2012-03-31"},{"nctId":"NCT01388491","phase":"PHASE2","title":"A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-10-31","conditions":["Hemostasis","Oral Contraceptive"],"enrollment":293,"completionDate":"2012-09-30"},{"nctId":"NCT05135013","phase":"","title":"The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study","status":"UNKNOWN","sponsor":"NewGiza University","startDate":"2021-11-16","conditions":["Observational Study"],"enrollment":200,"completionDate":"2022-03-31"},{"nctId":"NCT00447863","phase":"PHASE1","title":"Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-08","conditions":["Contraception"],"enrollment":0,"completionDate":"2007-08"},{"nctId":"NCT04979091","phase":"","title":"Sex Hormone Dysregulations Are Associated With Critical Illness in COVID-19 Patients","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-03-08","conditions":["Covid19","Critical Illness"],"enrollment":100,"completionDate":"2021-05-31"},{"nctId":"NCT02002260","phase":"NA","title":"Stopping Heavy Periods Project","status":"UNKNOWN","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2013-02","conditions":["Abnormal Uterine Bleeding","Abnormal Uterine Bleeding, Ovulatory Dysfunction","Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction"],"enrollment":59,"completionDate":"2021-12-31"},{"nctId":"NCT04615767","phase":"NA","title":"D-chiro-inositol Increases Androgens and Reduces Estrogens in Human Serum","status":"COMPLETED","sponsor":"AGUNCO Obstetrics and Gynecology Centre","startDate":"2020-10-28","conditions":["Low Serum Testosterone Levels in Man"],"enrollment":10,"completionDate":"2020-12-16"},{"nctId":"NCT03949985","phase":"","title":"Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2018-10-08","conditions":["Venous Thromboembolism","Contraception"],"enrollment":103,"completionDate":"2020-09-14"},{"nctId":"NCT04713904","phase":"PHASE1","title":"Bioavailability of Clormadinone/Ethinyl Estradiol Tablets 2 mg/0.02 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2021-01-16","conditions":["Bioequivalence"],"enrollment":38,"completionDate":"2021-02-02"},{"nctId":"NCT00873483","phase":"PHASE2","title":"US Ovulation Inhibition Study in Obese Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04-30","conditions":["Contraception"],"enrollment":173,"completionDate":"2010-03-03"},{"nctId":"NCT03890341","phase":"PHASE1","title":"Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-01","conditions":["Healthy"],"enrollment":0,"completionDate":"2021-11-01"},{"nctId":"NCT04194905","phase":"PHASE1","title":"Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2020-11-21","conditions":["Bioequivalence"],"enrollment":10,"completionDate":"2020-12-15"},{"nctId":"NCT04230070","phase":"PHASE1","title":"Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2020-10-24","conditions":["Bioequivalence"],"enrollment":30,"completionDate":"2020-11-17"},{"nctId":"NCT04267250","phase":"PHASE1","title":"Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-08-24","conditions":["Healthy Female Volunteers"],"enrollment":18,"completionDate":"2020-11-06"},{"nctId":"NCT00662454","phase":"PHASE4","title":"Oral Contraceptive Efficacy and Body Weight","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-01","conditions":["Contraception","Body Weight"],"enrollment":120,"completionDate":"2006-05"},{"nctId":"NCT02036879","phase":"EARLY_PHASE1","title":"Gender Disparity and Hormones in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-02","conditions":["Cystic Fibrosis (CF)"],"enrollment":55,"completionDate":"2018-08"},{"nctId":"NCT03984825","phase":"PHASE1","title":"Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-06-13","conditions":["HIV Infections"],"enrollment":23,"completionDate":"2019-08-16"},{"nctId":"NCT04513405","phase":"NA","title":"Estrogens Levels and Receptors Status and Skin Tears","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-09-01","conditions":["Skin Tear","Estrogen Deficiency"],"enrollment":1200,"completionDate":"2022-09-01"},{"nctId":"NCT01805817","phase":"PHASE4","title":"Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality","status":"WITHDRAWN","sponsor":"Istanbul Training and Research Hospital","startDate":"2012-12","conditions":["Contraceptive Methods Comparison"],"enrollment":0,"completionDate":""},{"nctId":"NCT01519401","phase":"NA","title":"Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2010-02","conditions":["Polycystic Ovary Syndrome","Estro-progestin Drugs"],"enrollment":50,"completionDate":"2011-07"},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":["Biological Availability"],"enrollment":68,"completionDate":"2019-02-19"},{"nctId":"NCT03662516","phase":"PHASE1","title":"A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-26","conditions":["Healthy Females"],"enrollment":17,"completionDate":"2019-01-19"},{"nctId":"NCT04142762","phase":"PHASE1","title":"A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2019-10-18","conditions":["Chronic Hepatitis B"],"enrollment":80,"completionDate":"2020-01-29"},{"nctId":"NCT02922127","phase":"PHASE1","title":"Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2016-12-16","conditions":["Contraception"],"enrollment":29,"completionDate":"2019-10-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Liquid","formulations":[{"form":"LIQUID","route":"ORAL","productName":"Dairy Allergen Mix"},{"form":"LIQUID","route":"ORAL","productName":"EBV/CFS Plus"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146811","MMSL":"2450","NDDF":"001270","UNII":"2DI9HA706A","VUID":"4022631","CHEBI":"CHEBI:17263","VANDF":"4018489","INN_ID":"407","RXNORM":"4103","UMLSCUI":"C0014942","chemblId":"CHEMBL494753","ChEMBL_ID":"CHEMBL1405","KEGG_DRUG":"D00067","DRUGBANK_ID":"DB00655","PDB_CHEM_ID":" J3Z","PUBCHEM_CID":"5870","SNOMEDCT_US":"51775003","IUPHAR_LIGAND_ID":"2818","MESH_DESCRIPTOR_UI":"D004970"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1979-","companyName":"Watson Labs","relationship":"Original Developer"}],"publicationCount":10585,"therapeuticAreas":["Dermatology"],"atcClassification":{"source":"DrugCentral","atcCode":"G03CA07","allCodes":["G03CA07","G03CC04"]},"biosimilarFilings":[],"originalDeveloper":"Watson Labs","recentPublications":[{"date":"2026 Mar 27","pmid":"41905481","title":"Synthesis of 2-aryl/alkylaminomethyl 17-sulfamate/17-methyl estratrienes and their in vitro cytotoxicity in human cancer cell cultures.","journal":"Steroids"},{"date":"2026 Mar 17","pmid":"41898861","title":"Transcriptional Activation of Estrogen Receptor-Alpha and Estrogen Receptor-Beta from Elephant Shark (Callorhynchus milii).","journal":"Genes"},{"date":"2025","pmid":"41884656","title":"Review of the effect of atrazine on the HPG axes and steroidogenic pathways in males: relevance for testicular and prostate cancer.","journal":"Frontiers in toxicology"},{"date":"2026 Mar 20","pmid":"41883375","title":"Per- and Polyfluoroalkyl Substance Exposure Associated with Later Puberty in Norwegian Girls: Data from the Bergen Growth Study 2.","journal":"Environment & health (Washington, D.C.)"},{"date":"2026 Mar 22","pmid":"41876050","title":"Exploring the multiple photochemical behaviors of ionizable EDCs in aquatic environments: Kinetics, intermediates, and toxicity evolution.","journal":"Environmental research"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Dr Reddys","Watson Labs","Wyeth Ayerst"],"status":"approved","companyName":"Watson Labs","companyId":"watson-labs","modality":"Small molecule","firstApprovalDate":"1979","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1979-02-21T00:00:00.000Z","mah":"WATSON LABS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:55:24.876429+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}